The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

PDF] Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.

Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery

Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug- resistant breast cancer via nanoscale drug delivery platforms - ScienceDirect

Full article: Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

October, 2022

Frontiers Nanodrug delivery in reversing multidrug resistance in cancer cells

Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders

Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery

PDF] Regulations of P-Glycoprotein/ABCB1/MDR1 in Human Cancer Cells

Lapatinib May Boost Effectiveness of Drugs That Destroy Cancer Proteins by Blocking Resistance

Drug resistance: from bacteria to cancer

Cancers, Free Full-Text

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells